Centralized R&D input service credit can be distributed to registered manufacturing units when direct nexus to manufacture exists &D

CESTAT HYDERABAD - AT allowed the appeal, setting aside the impugned orders and holding that CENVAT credit on input services consumed by a centralized R&D/IPDO unit may be distributed to manufacturing units where the assessee is registered as an input service distributor. The Tribunal recognized the pharmaceutical industry as specialised, permitting a single R&D unit to service multiple plants and finding a direct nexus between R&D services and manufacture. The decision follows CESTAT ALLAHABAD's view, upheld by the SC.

---

---

Issues Involved:
Whether CENVAT Credit is admissible on input services used in an Integrated Product Development Organisation Unit (IPDO) for a pharmaceutical manufacturer.

Analysis:
The judgment dealt with the issue of whether a pharmaceutical manufacturer is entitled to claim CENVAT Credit on input services used in their IPDO. The appellant, a major manufacturer of bulk drugs and formulations, created an IPDO for research and development activities. The Revenue contended that as the IPDO is not a manufacturer of excisable goods or provider of taxable services, no CENVAT Credit is admissible on the input services used in the IPDO. The appellant argued that there is a direct correlation between the services used in the IPDO and the manufacture of final products, thus entitling them to claim CENVAT Credit. The key question was whether the appellant could avail CENVAT Credit on the input services used in the IPDO. The appellant had also taken registration as an Input Service Distributor and distributed the credit taken in the IPDO to their manufacturing units.

The Tribunal considered the arguments and examined the nature of the pharmaceutical industry, emphasizing the importance of research and development in the manufacturing process. It noted that certifications, quality control, and regulatory clearances are crucial for producing marketable pharmaceutical products. The Tribunal highlighted that research and development are integral to the pharmaceutical industry, distinguishing products and incurring significant costs. It was established that services used in the R&D have a direct nexus with the manufacture of final products, even if the R&D unit is not physically located within the manufacturing units. The Tribunal found that the appellant, as an input service distributor, was entitled to distribute the CENVAT Credit availed on services used in the IPDO to various manufacturing units.

The Tribunal relied on precedent cases, including the decision of the Tribunal Allahabad and the Hon'ble Supreme Court, which supported the appellant's position. The judgments in similar cases were cited to establish that the issue was no longer res integra and had been decided in favor of the appellant. Consequently, the impugned orders were deemed unsustainable, and the appeals were allowed, setting aside the orders with consequential relief granted to the appellant.

---